Viracta Therapeutics, Inc. Major Shareholders & Ownership History
| Major Shareholder Name | Reporting Date | Shares Held | Market Value | Change in Shares | Ownership |
|---|---|---|---|---|---|
| CITADEL ADVISORS LLC | 11/14/2024 | 1.52 M | $351,784 | 0.00% | 3.84% |
| VANGUARD GROUP INC | 11/13/2024 | 954,485 | $220,486 | -17.81% | 2.41% |
| SAMSARA BIOCAPITAL, LLC | 11/14/2024 | 689,709 | $159,599 | 0.00% | 1.74% |
| STONEPINE CAPITAL MANAGEMENT, LLC | 11/13/2024 | 500,000 | $115,700 | 100.00% | 1.26% |
| LAURION CAPITAL MANAGEMENT LP | 11/14/2024 | 332,189 | $76,869 | -18.44% | 0.84% |
| AISLING CAPITAL MANAGEMENT LP | 11/13/2024 | 288,571 | $66,371 | 0.00% | 0.73% |
| GEODE CAPITAL MANAGEMENT, LLC | 11/12/2024 | 250,007 | $57,866 | -7.67% | 0.63% |
| RENAISSANCE TECHNOLOGIES LLC | 11/13/2024 | 245,399 | $56,785 | 12.72% | 0.62% |
| BLACKROCK FUNDING, INC. /DE | 11/13/2024 | 234,846 | $54,343 | 100.00% | 0.59% |
| HRT FINANCIAL LP | 11/12/2024 | 138,822 | $32,000 | 100.00% | 0.35% |
| LANDSCAPE CAPITAL MANAGEMENT, L.L.C. | 11/08/2024 | 68,317 | $15,809 | 100.00% | 0.17% |
| STATE STREET CORP | 11/14/2024 | 65,867 | $15,242 | 0.00% | 0.17% |
| UNITED CAPITAL FINANCIAL ADVISERS, LLC | 11/12/2024 | 42,995 | $9,889 | 100.00% | 0.11% |
| MORGAN STANLEY | 11/14/2024 | 30,669 | $7,097 | -77.21% | 0.08% |
| GOLDMAN SACHS GROUP INC | 11/14/2024 | 27,090 | $6,269 | 100.00% | 0.07% |
| INSPIRION WEALTH ADVISORS, LLC | 10/04/2024 | 25,000 | $5,785 | 66.67% | 0.06% |
| ROYAL BANK OF CANADA | 11/14/2024 | 20,000 | $5,000 | 100.00% | 0.05% |
| WEALTHTRUST AXIOM LLC | 11/13/2024 | 16,396 | $3,794 | 43.88% | 0.04% |
| BANK OF AMERICA CORP /DE/ | 11/14/2024 | 15,054 | $3,477 | 20.47% | 0.04% |
| COLONY GROUP, LLC | 11/14/2024 | 14,000 | $3,240 | 100.00% | 0.04% |
| TOWER RESEARCH CAPITAL LLC (TRC) | 11/14/2024 | 13,870 | $3,204 | 9.63% | 0.04% |
| TRUST CO OF TOLEDO NA /OH/ | 10/02/2024 | 12,317 | $2,850 | 0.00% | 0.03% |
| ACADIAN ASSET MANAGEMENT LLC | 11/12/2024 | 10,908 | $2,000 | 0.00% | 0.03% |
| XTX TOPCO LTD | 11/14/2024 | 10,174 | $2,354 | -47.01% | 0.03% |
| PLANNING CAPITAL MANAGEMENT CORP | 11/06/2024 | 7,272 | $1,683 | 0.00% | 0.02% |
| DUNHILL FINANCIAL, LLC | 11/15/2024 | 5,000 | $1,157 | 100.00% | 0.01% |
| RP MANAGEMENT, LLC | 11/13/2024 | 3,700 | $851 | 0.00% | 0.01% |
| IAG WEALTH PARTNERS, LLC | 10/29/2024 | 3,000 | $694 | 0.00% | 0.01% |
| OARSMAN CAPITAL, INC. | 11/08/2024 | 1,000 | $231 | 100.00% | 0.00% |
| JONES FINANCIAL COMPANIES LLLP | 11/12/2024 | 1,000 | $222 | 100.00% | 0.00% |
| JPMORGAN CHASE & CO | 11/08/2024 | 721 | $167 | 0.00% | 0.00% |
| INDIANA TRUST & INVESTMENT MANAGEMENT CO | 10/16/2024 | 200 | $46 | 0.00% | 0.00% |
| WELLS FARGO & COMPANY/MN | 11/13/2024 | 171 | $40 | 0.00% | 0.00% |
| UBS GROUP AG | 11/14/2024 | 95 | $22 | -94.38% | 0.00% |
| PARALLEL ADVISORS, LLC | 11/13/2024 | 8 | $2 | 0.00% | 0.00% |
| ADDISON ADVISORS LLC | 11/04/2024 | 4 | $1 | 0.00% | 0.00% |
| BARCLAYS PLC | 11/19/2024 | 0 | $0 | -100.00% | 0.00% |
| MAI CAPITAL MANAGEMENT | 11/07/2024 | 0 | $0 | -100.00% | 0.00% |
| BVF INC/IL | 11/14/2024 | 0 | $0 | -100.00% | 0.00% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 11/14/2024 | 0 | $0 | -100.00% | 0.00% |
| CITADEL ADVISORS LLC | 11/14/2024 | 0 | $0 | -100.00% | 0.00% |
| ENSIGN PEAK ADVISORS, INC | 11/14/2024 | 0 | $0 | -100.00% | 0.00% |
| SIMPLEX TRADING, LLC | 11/08/2024 | 0 | $0 | -100.00% | 0.00% |
| VIRTU FINANCIAL LLC | 11/20/2024 | 0 | $0 | -100.00% | 0.00% |
| NEWEDGE ADVISORS, LLC | 11/14/2024 | 0 | $0 | -100.00% | 0.00% |
| QUBE RESEARCH & TECHNOLOGIES LTD | 11/14/2024 | 0 | $0 | -100.00% | 0.00% |
| BEACON POINTE ADVISORS, LLC | 11/14/2024 | 0 | $0 | -100.00% | 0.00% |
Viracta Therapeutics, Inc.institutional Ownership - FAQ's
During the previous two years, 53 institutional investors and hedge funds held shares of Viracta Therapeutics, Inc.. The most heavily invested institutionals were:
CITADEL ADVISORS LLC: 1.52 M
VANGUARD GROUP INC: 954,485
Samsara BioCapital, LLC: 689,709
Stonepine Capital Management, LLC: 500,000
Laurion Capital Management LP: 332,189
Aisling Capital Management LP: 288,571
14.12% of Viracta Therapeutics, Inc. stock is owned by institutional investors.
Institutional investors have bought a total of 5.91 M shares in the last 24 months. This purchase volume represents approximately $1.48 M in transactions.